HBsAg Status, Molecular Detection and Therapy Evaluation of Hepatitis B Patient
Downloads
The management of chronic hepatitis B involves various therapeutic approaches, including nucleotide analogs (NUCs) and pegylated-interferon alpha (peg-IFN), either in isolation or in combination. Reverse transcriptase enzyme is competitively inhibited by NUCs, which effectively suppresses HBV replication and lowers viral load. Concerning their cost-effectiveness, high response rates, low side effects, and oral administration, NUCs are recommended. Prolonged use, particularly of NUCs with a low genetic barrier or as monotherapy, can, however, lead to resistance, long-term safety issues, and the need for ongoing treatment. Physicians and other healthcare professionals are extremely concerned about the emergence of resistance and possible safety concerns related to the long-term use of NUCs. Moreover, the requirement for continuous therapy presents notable obstacles concerning patient adherence, distribution of healthcare resources, and overall economic viability. To clarify these problems and direct the creation of more potent and long-lasting treatment plans for chronic hepatitis B, urgent research is required. Hepatitis B surface antigen (HBsAg) detection is frequently accomplished via the use of the Chemiluminescent Microparticle Immunoassay (CMIA), which is a crucial early serologic marker for screening and diagnosis. Polymerase chain reaction (PCR) molecular testing is employed to confirm the presence of HBsAg. Polymerase Chain Reaction (PCR) was the technique we utilized to verify the outcomes. Twenty-eight of the HBsAg-positive patients at W.Z. Johannes Kupang Hospital had positive PCR results, highlighting the significance of molecular confirmation. The results of this study emphasize the value of precise HBsAg testing and the supplementary function of molecular confirmation in the treatment of patients with chronic hepatitis B. Furthermore, it clarifies the current therapeutic approaches applied to this patient population, highlighting the necessity of customized therapeutic approaches based on each patient's unique profile and potential complications.
Abdul Basit, S., Dawood, A., Ryan, J., & Gish, R. (2017). Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert review of clinical pharmacology, 10(7), 707-716. https://doi.org/10.1080/17512433.2017.1323633
Agarwal, K., Fung, S. K., Nguyen, T. T., Cheng, W., Sicard, E., Ryder, S. D., ... & Foster, G. R. (2015). Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. Journal of hepatology, 62(3), 533-540. https://doi.org/10.1016/j.jhep.2014.10.035
Bedre, R. H., Raj, U., Misra, S. P., & Varadwaj, P. K. (2016). Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials. Indian Journal of Gastroenterology, 35, 75-82. https://doi.org/10.1007/s12664-016-0632-5
Borgia, G., Carleo, M. A., Gaeta, G. B., & Gentile, I. (2012). Hepatitis B in pregnancy. World journal of gastroenterology: WJG, 18(34), 4677–4683. https://doi.org/10.3748/wjg.v18.i34.4677
Conners, E. E., Panagiotakopoulos, L., Hofmeister, M. G., Spradling, P. R., Hagan, L. M., Harris, A. M., ... & Wang, S. H. (2023). Screening and testing for hepatitis B virus infection: CDC recommendations—United States, 2023. MMWR Recommendations and Reports, 72(1): 1–25. https://doi.org/10.15585/mmwr.rr7201a1
Fadrian, F. (2016). Terapi Antiviral Pada Sirosis Hati Dekompensata Terkait Infeksi Virus Hepatitis B. Majalah Kedokteran Andalas, 39(1), 35-41.
Fahira, A., & Hasan, I. (2020). Higher Risk of Hepatocellular Carcinoma Progression in the Population of Untreated Immune-Tolerant Phase Chronic Hepatitis B Patients: An Evidence Based. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 21(1), 68-78. https://doi.org/10.24871/211202068-78
Hindarto, C. K., Rostinawati, T., & Retnoningrum, D. S. (2011). Identifikasi Mutasi Pada Daerah Dna Polimerase Dan Hbsag Virus Hepatitis B. Fitofarmaka: Jurnal Ilmiah Farmasi, 1(2), 22-30. https://doi.org/10.33751/jf.v1i2.161
Jackson, K., Locarnini, S., & Gish, R. (2018). Diagnostics of hepatitis B virus: standard of care and investigational. Clinical liver disease, 12(1), 5. https://doi.org/10.1002/cld.729
Jefferies, M., Rauff, B., Rashid, H., Lam, T., & Rafiq, S. (2018). Update on global epidemiology of viral hepatitis and preventive strategies. World journal of clinical cases, 6(13), 589. http://doi.org/10.12998/wjcc.v6.i13.589
Kambuno, N. T., Sari, A., Nurdin, K. E., Novicadlitha, Y., & Siregar, I. (2018, December). The relation of blood donors’ characteristic toward prevalences of HBsAg and anti-HCV on Blood Transfussion Unit of PMI in Province of East Nusa Tenggara. In Proceeding 1st. International Conference Health Polytechnic of Kupang , 303-310.
Kementerian Kesehatan Republik Indonesia. (2018). Hasil Utama RISKESDAS 2018. Kementerian Kesehatan Republik Indonesia.
Kim, B. H., & Kim, W. R. (2018). Epidemiology of hepatitis B virus infection in the United States. Clinical liver disease, 12(1), 1-4. https://doi.org/10.1002/cld.732
Khairani, N., Siregar, T. M., Frisnoiry, S., Manullang, S., & Hasibuan, N. I. (2022, December). SEIR Model in Spread Disease. Proceedings of the 4th International Conference on Innovation in Education, Science and Culture, ICIESC 2022, 11 October 2022, Medan, Indonesia.
Muljono, D. H. (2017). Epidemiology of hepatitis B and C in Republic of Indonesia. Euroasian journal of hepato-gastroenterology, 7(1), 55. https://doi.org/10.5005/jp-journals-l0018-1212
Nugraha, E. S., Supriami, S. H., Atik, N., Agustanti, N., Wahyudi, Y., Girawan, D., ... & Abdurachman, S. A. (2022). Antiviral Treatment and One-Year Follow-Up of Chronic Hepatitis B Patients in Bandung: An Observational Study. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 23(2), 117-122. https://doi.org/10.24871/2322022217-222
Nurainy, N., & Muljono, D. H. (2018) Karakteristik Reverse Transcriptase Gen Polymerase Virus Hepatitis B Pada Penderita Hepatitis B Kronis Asimptomatik Pra-Pengobatan. Ejki, 5(3),183-190.
Robinson, A., Wong, R., & Gish, R. G. (2023). Chronic hepatitis B virus and hepatitis D virus: new developments. Clinics in Liver Disease, 27(1), 17-25. https://doi.org/10.1016/j.cld.2022.08.001
Seto, A. R. (2019). Hubungan Jumlah Dan Aktivitas Sel Nk Dengan Kekakuan Hati Pada Pasien Hepatitis B Kronik Penelitian Observasional Analitik Cross-Sectional di Instalasi Rawat Jalan Divisi Gasteroenterologi–Hepatologi Departemen Ilmu Penyakit Dalam RSUD Dr. Soetomo Surabaya. Thesis. Universitas Airlangga.
Sulaiman, A. S., Hasan, I., Lesmana, C. R. A., Jasirwan, C. O. M., Nababan, S. H. H., Kalista, K. F., ... & Gani, R. A. (2021). Analog nukleosida/nukleotida sebagai terapi hepatitis B kronis: studi kohort 3 tahun. Jurnal Penyakit Dalam Indonesia, 8(3), 139-145.
Tiollais, P., Pourcel, C., & Dejean, A. (1985). The hepatitis B virus. Nature, 317(6037), 489-495.
Trisnaningtyas, R. W., Sari, C. P., & Setyaningrum, N. (2017). Evaluasi Terapi Pada Pasien Hepatitis B di RSUP Dr. Sardjito Yogyakarta. Jurnal Ilmiah Farmasi, 13(1), 29-34.
Wibowo, B. P., Susanto, E., Supriono, S., & Mustika, S. (2020). Perbandingan Potensi Telbivudin Dan Tenofovir Dalam Menurunkan Skor Aspartate Transaminase To Platelet Ratio Index (Apri) Pada Pasien Hepatitis B. Majalah Kesehatan Fkub, 7(1), 41-47. https://doi.org/10.21776/ub.majalahkesehatan.2020.007.01.5
Winata, A. (2017). Identifikasi hasil Hepatitis B Surface Antigen (HBsAg) Pada Perawat yang Bekerja Di Ruang Infeksi Rumah Sakit Umum Bahteramas Provinsi Sulawesi Tenggara. Karya Tulis Ilmiah. Poltekkes Kemenkes Kendari.
Wijayadi, T., Sjahril, R., Ie, S. I., Wahyuni, R., Pattelongi, I., Massi, M. N., ... & Muljono, D.H. (2018). Seroepidemiology of HBV infection among health-care workers in South Sulawesi, Indonesia. BMC Infectious Diseases, 18, 279. https://doi.org/10.1186/s12879-018-3190-x
World Health Organization (2016). Global health sector strategy on viral hepatitis: Towards Ending Viral Hepatitis 2016-2021 [Internet]. Geneva: World Health Organization.
World Health Organization. (2016). Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Geneva: World Health Organization.
Yulia, D. (2020). Virus Hepatitis B Ditinjau dari Aspek Laboratorium. Jurnal Kesehatan Andalas, 8(4). https://doi.org/10.25077/jka.v8i4.1108
Zampino, R., Boemio, A., Sagnelli, C., Alessio, L., Adinolfi, L. E., Sagnelli, E., & Coppola, N. (2015). Hepatitis B virus burden in developing countries. World journal of gastroenterology, 21(42), 11941–11953. https://doi.org/10.3748/wjg.v21.i42.11941
Zoulim, F., & Perrillo, R. (2008). Hepatitis B: reflections on the current approach to antiviral therapy. Journal of hepatology, 48 (Supplement 1), S1-S19. https://doi.org/10.1016/j.jhep.2008.01.011
Copyright (c) 2023 JURNAL INFO KESEHATAN
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright notice
Ownership of copyright
The copyright in this website and the material on this website (including without limitation the text, computer code, artwork, photographs, images, music, audio material, video material and audio-visual material on this website) is owned by JURNAL INFO KESEHATAN and its licensors.
Copyright license
JURNAL INFO KESEHATAN grants to you a worldwide non-exclusive royalty-free revocable license to:
- view this website and the material on this website on a computer or mobile device via a web browser;
- copy and store this website and the material on this website in your web browser cache memory; and
- print pages from this website for your use.
- All articles published by JURNAL INFO KESEHATAN are licensed under the Creative Commons Attribution 4.0 International License. This permits anyone to copy, redistribute, remix, transmit and adapt the work provided the original work and source is appropriately cited.
JURNAL INFO KESEHATAN does not grant you any other rights in relation to this website or the material on this website. In other words, all other rights are reserved.
For the avoidance of doubt, you must not adapt, edit, change, transform, publish, republish, distribute, redistribute, broadcast, rebroadcast or show or play in public this website or the material on this website (in any form or media) without appropriately and conspicuously citing the original work and source or JURNAL INFO KESEHATAN prior written permission.
Permissions
You may request permission to use the copyright materials on this website by writing to jurnalinfokesehatan@gmail.com.
Enforcement of copyright
JURNAL INFO KESEHATAN takes the protection of its copyright very seriously.
If JURNAL INFO KESEHATAN discovers that you have used its copyright materials in contravention of the license above, JURNAL INFO KESEHATAN may bring legal proceedings against you seeking monetary damages and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of JURNAL INFO KESEHATAN copyright materials that contravenes or may contravene the license above, please report this by email to jurnalinfokesehatan@gmail.com
Infringing material
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to jurnalinfokesehatan@gmail.com.
